Core Insights - Profusa, Inc. has expanded its commercial footprint in Europe for its Lumee Oxygen platform by signing a letter of intent with Angiopro GmbH, targeting initial markets such as Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia [1][3] - The partnership with Angiopro enhances Profusa's distributor channel coverage to approximately 35% of the European Union population, facilitating around 300,000 annual endovascular procedures [1][3] - Profusa's Lumee platform technology addresses a global market estimated at over $10.5 billion across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to deliver long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for individuals [4] Partnership Details - Angiopro GmbH is a specialized MedTech distributor with expertise in cardiovascular technologies, aiming to enhance patient care and drive commercial success [2] - The collaboration is expected to leverage Angiopro's marketing, sales infrastructure, and regulatory expertise to establish a strong foundation for long-term growth with Profusa [2]

Core Insights - Profusa, Inc. has expanded its commercial footprint in Europe for its Lumee Oxygen platform by signing a letter of intent with Angiopro GmbH, targeting initial markets such as Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia [1][3] - The partnership with Angiopro enhances Profusa's distributor channel coverage to approximately 35% of the European Union population, facilitating around 300,000 annual endovascular procedures [1][3] - Profusa's Lumee platform technology addresses a global addressable market exceeding $10.5 billion across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to deliver long-lasting, injectable, and affordable biosensors, along with an intelligent data platform, to create personalized biochemical signatures for clinical use [4] Partnership Details - Angiopro GmbH is a specialized MedTech distributor with expertise in cardiovascular technologies, aiming to enhance patient care and drive commercial success [2] - The collaboration is expected to leverage Angiopro's marketing, sales infrastructure, regulatory expertise, and established networks across Europe to support Profusa's growth strategy [2]

Core Insights - Profusa, Inc. has announced a collaboration with Prof. Dr. Marianne Brodmann from the Medical University of Graz, Austria, to adopt the Lumee oxygen platform technology in her practice, which involves approximately 1,500 annual vascular procedures [1][2] - Prof. Brodmann, as the principal investigator of clinical studies that supported Lumee oxygen's CE marking, will integrate Profusa's platform technology into clinical study programs [1][2] - The collaboration aims to validate the Lumee technology platform and expand its market reach through integration into clinical practices [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to offer long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for reliable clinical use [4]

Core Insights - Profusa, Inc. has signed a Letter of Intent to establish a distribution agreement in Spain for its Lumee Oxygen platform, partnering with Dismeval, S.L. [1][2] - The partnership aims to enhance Profusa's distribution infrastructure in Europe, targeting a global addressable market exceeding $10.5 billion for its tissue oxygen technology across three medical indications [2][3] - Profusa's technology addresses a significant clinical need in Europe, with over 300,000 endovascular procedures performed annually [2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical data [3] - The company aims to deliver long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for reliable clinical use [3]